Canaccord downgraded Regulus (RGLS) to Hold from Buy with a price target of $11, down from $28, after the company agreed to be acquired by Novartis (NVS) for $7 per share in cash and a $7 per share contingent value right.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGLS:
- Regulus downgraded to Hold from Buy at JonesResearch
- Regulus Announces Merger Agreement with Novartis
- Regulus to be acquired by Novartis for $7.00 per share in cash
- Promising Phase 1b Results and Favorable Safety Profile Position Regulus’s Farabursen as a Strong Investment in ADPKD Treatment
- Promising Phase 1b Results and Future Prospects Drive Buy Rating for Regulus’s Farabursen